TriSalus Life Sciences, Inc. (NASDAQ: TLSI)

This investigation is for anyone who acquired securities in TriSalus Life Sciences, Inc. (NASDAQ: TLSI) prior to May 12, 2026.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by telling investors that the Company would receive FDA approval for TriNav Advance when the Company knew that it would not receive the approval.

On May 12, 2026, TriSalus reported first quarter results, including revenue of $8.90M, a decline of 2.92% year over year. The Company further announced a cut to full year revenue guidance to $54 million to $57, a cut of $5.5 million at the midpoint compared to prior guidance. In the accompanying earnings call, management explained “the driver of this revision includes both the lower Q1 revenues from the commercial expansion and the delayed FDA clearance timing for TriNav Advance.” Management further stated FDA clearance for TriNav Advance “is now running approximately 5 months past the 30-day MDUFA review goal.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in TriSalus Life Sciences, Inc. (NASDAQ: TLSI) prior to May 12, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.